SPECTRUM PHARMACEUTICALS INC Form 8-K May 24, 2007

#### **Table of Contents**

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 24, 2007 Spectrum Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware000-2878293-0979187(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

157 Technology Drive 92618
Irvine, California (Zip Code)

(Address of principal executive offices)

(949) 788-6700

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## **TABLE OF CONTENTS**

<u>Item 8.01.</u> <u>Other Events.</u> <u>SIGNATURE</u>

## **Table of Contents**

### Item 8.01. Other Events.

As of May 24, 2007, Spectrum Pharmaceuticals, Inc. has approximately \$75 million in cash, cash equivalents and marketable securities, and 30,805,259 shares of common stock issued and outstanding.

#### **Table of Contents**

### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SPECTRUM PHARMACEUTICALS, INC.

BY: /s/ SHYAM KUMARIA Shyam Kumaria Vice President, Finance

Date: May 24, 2007